宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

交易中 01-12 11:41:24

6.310

-0.010

-0.16%

最高6.700	最低6.250	成交量67.54万
今开6.550	昨收6.320	日振幅7.12%
总市值27.26亿	流通市值26.50亿	总股本4.32亿
成交额433.51万	换手率0.16%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":6.31,"timestamp":1768189220150,"preClose":6.32,"halted":0,"volume":675400,"delay":0,"floatShares":420000000,"shares":432000000,"eps":-0.9361860449720191,"marketStatus":"交易中","change":-0.01,"latestTime":"01-12 11:41:24","open":6.55,"high":6.7,"low":6.25,"amount":4335092,"amplitude":0.071203,"askPrice":6.34,"askSize":5400,"bidPrice":6.31,"bidSize":15200,"shortable":3,"etf":0,"ttmEps":-0.859371049180839,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1768190400000},"marketStatusCode":2,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":6.32,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.910753,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"2602348445","title":"每日卖空追踪 | 宜明昂科-B 01月08日卖空量成交4.88万股，卖空比例为2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348445","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602348445?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861023,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间01月08日，跌5.19%，卖空量成交4.88万股，较上一交易日减少43.52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164531a4ab4395&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164531a4ab4395&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2601540653","title":"国元国际：宜明昂科-B(01541)重获IMM2510全球权利 海外研发有望加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2601540653","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601540653?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:09","pubTimestamp":1767856165,"startTime":"0","endTime":"0","summary":"公司与Axion订立终止协议，收回此前授予Axion的全球开发及商业化权利，仅保留Axion逐步结束临床开发活动的有限许可。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260108/20260108151004_11502.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260108/20260108151004_11502.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2601316386","title":"3500万美元到账后，宜明昂科超20亿美元BD合作终止，创始人田文志：美国临床推进缓慢","url":"https://stock-news.laohu8.com/highlight/detail?id=2601316386","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601316386?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:19","pubTimestamp":1767784795,"startTime":"0","endTime":"0","summary":"宜明昂科为何与美国药企终止协议？此次终止不影响宜明昂科已从Axion收到的3500万美元首付款和里程碑付款。临床试验进展乏力成为此次合作终止的导火索。去年8月是宜明昂科最后一次收到BD交易款项，过往五次总计金额为3500万美元，这也是此次交易终止时不可退还的款项。随着BD款项陆续到账，双方的合作项目也在持续推进。但实际上，在2026年开年不到一周，宜明昂科与Instil Bio双方就终止了合作。据公开资料，其于2025年4月开始担任这一职位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107192006a6fe8396&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107192006a6fe8396&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516902.SGD","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","LU2778985437.USD","LU1961090484.USD","LU0540923850.HKD","BK1161","01541","LU0348825331.USD","LU2399975544.HKD","IE00BPRC5H50.USD","09926","LU0634319403.HKD","LU0348735423.USD","LU0348783233.USD","LU0348784397.USD","LU0417516571.SGD","LU0561508036.HKD","LU0348767384.USD","LU2476274720.SGD","LU2476274308.USD","LU0348827113.USD","LU1720050803.USD","TIL","LU0417516738.SGD","LU0348766576.USD","LU1794554557.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2601849078","title":"收回海外权益 宜明昂科(01541)战略纠偏打开新空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2601849078","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601849078?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:00","pubTimestamp":1767744020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科昨天盘后宣布从Instil Bio收回IMM2510和IMM27M的全球权益，标志着公司主动修正了之前的授权策略。宜明昂科另一核心看点是CD47系列管线。随后该领域陆续落地了多项早期平台型合作，证明了MCE的战略价值。宜明昂科的IMM0306是进展最快的MCE分子之一。综合来看，此次权益回收让宜明昂科重新掌握重要资产主导权，叠加IMM01、IMM0306管线在肿瘤和自免领域的差异化布局，公司后续临床进展和BD合作值得期待。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2601894641","title":"宜明昂科-B(01541)重获IMM2510及IMM27M的全球权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894641","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601894641?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:05","pubTimestamp":1767701120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，根据授权及合作协议，本公司同意授予Axion在大中华地区以外研究、开发及商业化若干靶向程序性细胞死亡配体1 及血管内皮生长因子的双特异性抗体，以及若干靶向细胞毒性T淋巴细胞相关蛋白4 的单克隆抗体的独家授权。是次终止将不影响本公司根据授权及合作协议已自Axion收取的首付款及里程碑付款3500万美元。宜明昂科欣然重获IMM2510及IMM27M的全球权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B(01541)重获IMM2510及IMM27M的全球权利","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1181195822","title":"宜明昂科-B：将重获Imm2510与Imm27m全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1181195822","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181195822?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:04","pubTimestamp":1767701052,"startTime":"0","endTime":"0","summary":"宜明昂科-B（ImmuneOnco Biopharmaceuticals Shanghai Inc）宣布，公司将重新获得其核心候选药物Imm2510与Imm27m的全球开发及商业化权利。此举标志着公司在推进其创新肿瘤免疫疗法管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2601985700","title":"宜明昂科-B盘中异动 早盘急速拉升5.04%报6.460港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601985700","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601985700?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:08","pubTimestamp":1767665293,"startTime":"0","endTime":"0","summary":"2026年01月06日早盘10时08分，宜明昂科-B股票出现异动，股价急速上涨5.04%。截至发稿，该股报6.460港元/股，成交量29.26万股，换手率0.07%，振幅3.41%。资金方面，该股资金流入111.02万港元，流出58.3796万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为1.16%。其相关个股中，中生北控生物科技、圣诺医药-B、晶泰控股涨幅较大，振幅较大的相关个股有中生北控生物科技、拨康视云-B、轩竹生物-B，振幅分别为22.83%、13.70%、10.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106100813a4a124b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106100813a4a124b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4585","06160","00013","BK4139","ONC","CXO","02509","BMS","01801","01167","01541"],"gpt_icon":0},{"id":"2601285357","title":"每日卖空追踪 | 宜明昂科-B 01月05日卖空量成交6.46万股，卖空比例为4.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601285357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601285357?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601821,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间01月05日，涨1.15%，卖空量成交6.46万股，较上一交易日增加85.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163419a49e27e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163419a49e27e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2595743922","title":"宜明昂科-B盘中异动 早盘大幅跳水5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595743922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595743922?lang=zh_cn&edition=full","pubTime":"2025-12-30 10:12","pubTimestamp":1767060751,"startTime":"0","endTime":"0","summary":"2025年12月30日早盘10时12分，宜明昂科-B股票出现波动，股价快速下挫5.19%。截至发稿，该股报5.850港元/股，成交量30.54万股，换手率0.07%，振幅5.02%。宜明昂科-B股票所在的生物技术行业中，整体跌幅为0.61%。其相关个股中，药捷安康-B、帝王国际投资、华昊中天医药-B涨幅较大，振幅较大的相关个股有药捷安康-B、华昊中天医药-B、华生物-B，振幅分别为20.71%、17.58%、8.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230101231a6df2f30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230101231a6df2f30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2595759313","title":"每日卖空追踪 | 宜明昂科-B 12月29日卖空量成交1.6万股，卖空比例为1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595759313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595759313?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:30","pubTimestamp":1766997021,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间12月29日，跌0.48%，卖空量成交1.6万股，较上一交易日减少43.66%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163250a48548db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163250a48548db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2594405434","title":"每日卖空追踪 | 宜明昂科-B 12月24日卖空量成交2.84万股，卖空比例为3.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594405434?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:30","pubTimestamp":1766565020,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间12月24日，涨2.31%，卖空量成交2.84万股，较上一交易日增加63.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224163306a4727e7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224163306a4727e7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2593243064","title":"每日卖空追踪 | 宜明昂科-B 12月22日卖空量成交8600股，卖空比例为0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593243064","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593243064?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392223,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间12月22日，涨1.44%，卖空量成交8600股，较上一交易日减少46.91%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163327a6c09a34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163327a6c09a34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2593648430","title":"宜明昂科-B12月22日获主力加仓68.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593648430","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593648430?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:15","pubTimestamp":1766391337,"startTime":"0","endTime":"0","summary":"12月22日, 宜明昂科-B股价涨1.44%，报收6.33元，成交金额571.1万元，换手率0.21%，振幅5.61%，量比1.34。宜明昂科-B今日主力资金净流入68.6万元，上一交易日主力净流入59.3万元。该股近5个交易日上涨1.93%，主力资金累计净流入97.1万元；近20日主力资金累计净流出502.8万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222161843a6c087e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222161843a6c087e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2592163413","title":"宜明昂科-B12月19日主力净流入59.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163413","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592163413?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132126,"startTime":"0","endTime":"0","summary":"12月19日, 宜明昂科-B股价涨3.14%，报收6.24元，成交金额363.2万元，换手率0.14%，振幅4.30%，量比0.90。宜明昂科-B今日主力资金净流入59.3万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.00%，主力资金累计净流出81.6万元；近20日主力资金累计净流出571.4万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161706a45f1fa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161706a45f1fa1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2592153445","title":"港股异动 | 宜明昂科-B(01541)涨近4% 自研阿沐瑞芙普α皮下制剂IMM0306S临床研究申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592153445","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592153445?lang=zh_cn&edition=full","pubTime":"2025-12-19 14:13","pubTimestamp":1766124833,"startTime":"0","endTime":"0","summary":"消息面上，据宜明昂科官微消息，12月18日，公司宣布，自主研发的、同时靶向CD47和CD20的双特异性抗体-受体重组蛋白药物阿沐瑞芙普αIMM0306S用于治疗系统性红斑狼疮的临床试验申请已正式获得国家药品监督管理局受理。IMM0306S是基于宜明昂科核心产品阿沐瑞芙普α开发的皮下制剂。值得一提的是，在第67届美国血液学会年会上，宜明昂科公布了阿沐瑞芙普α联合来那度胺治疗复发/难治性CD20阳性滤泡性淋巴瘤的I/II期临床研究数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2592163459","title":"宜明昂科阿沐瑞芙普α皮下制剂IMM0306S临床研究申请获受理，系统性红斑狼疮治疗迎新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163459","media":"抗体圈","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592163459?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:07","pubTimestamp":1766113634,"startTime":"0","endTime":"0","summary":"研究显示， IMM0306在治疗中至重度活动性SLE患者中展现出显著疗效和良好安全性。IMM0306S通过皮下注射方式给药，可显著降低血药浓度峰值并有效减少靶向血液毒性及脱靶效应，以进一步提高药物疗效。宜明昂科计划在III期临床试验中进一步验证IMM0306的疗效和安全性，以期为患者提供更安全有效的治疗方案。系统性红斑狼疮是一种严重的自身免疫性疾病，目前临床仍存在巨大未满足需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219111710a45e1b15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219111710a45e1b15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2592911679","title":"每日卖空追踪 | 宜明昂科-B 12月17日卖空量成交1.16万股，卖空比例为1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592911679?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960221,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间12月17日，跌1.3%，卖空量成交1.16万股，较上一交易日减少71.71%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163307a6ad2400&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163307a6ad2400&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2592931390","title":"2026年一个注定燃爆的BD方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931390","media":"药渡Daily","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592931390?lang=zh_cn&edition=full","pubTime":"2025-12-16 17:30","pubTimestamp":1765877458,"startTime":"0","endTime":"0","summary":"司美格鲁肽原研由诺和诺德开发，但随着其核心专利将于2026年3月到期，中国市场正在上演激烈的司美格鲁肽生物类似药争夺战。截至目前，国内已有10款国产司美格鲁肽申报上市，并有10款已进入临床III期阶段。展望减重领域的下一个BD热点，三靶点GLP-1或是其中之一。全球口服小分子GLP-1R激动剂研发管线（部分）图源：国金证券研报展望2026年，减脂不减肌药物、小核酸减重药物有望成为下一个BD“金矿”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216184301a6a93b82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216184301a6a93b82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02105","06887","01672","BK1515","01541"],"gpt_icon":0},{"id":"2592937580","title":"每日卖空追踪 | 宜明昂科-B 12月16日卖空量成交3.94万股，卖空比例为6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592937580?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:30","pubTimestamp":1765873820,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间12月16日，跌0.81%，卖空量成交3.94万股，较上一交易日增加126.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163303a6a8b4d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163303a6a8b4d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":0.0395},{"period":"1month","weight":-0.0581},{"period":"3month","weight":-0.4968},{"period":"6month","weight":-0.3804},{"period":"1year","weight":0.2224},{"period":"ytd","weight":0.084}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}